Wells Fargo & Company has filed a preliminary pricing supplement for its Medium-Term Notes, Series AA, which is a significant step in the bank's ongoing efforts to enhance its capital structure. The notes are set to mature on November 25, 2033, and will pay interest at a fixed rate of 5.85% per annum. This move is crucial for Wells Fargo as it seeks to secure long-term financing amid a competitive banking environment.
Wells Fargo, a prominent player in the banking industry, is classified under the SIC code 6021, which pertains to National Commercial Banks. The company trades on the New York Stock Exchange under the ticker symbol WFC, along with several preferred stock symbols. The latest filing, made on November 13, 2026, is part of a series of recent filings that indicate the bank's proactive approach to capital management.
The filing details that the notes will be redeemable by Wells Fargo at 100% of their principal amount, plus any accrued interest, starting from 1.5 years after issuance. This flexibility allows the bank to adapt to changing market conditions while providing investors with a predictable return. The filing states, "The notes are not subject to repayment at the option of any holder of the notes prior to the stated maturity date," ensuring that investors are committed for the long haul.
This strategic move may impact various stakeholders, including institutional investors and retail clients looking for stable investment options. The fixed interest rate and callable feature of the notes may attract investors seeking security in a fluctuating market. Additionally, Wells Fargo's decision to issue these notes could prompt competitors in the National Commercial Banks sector to evaluate their own capital strategies, potentially leading to increased offerings in the market.
Looking ahead, it remains to be seen how the market will respond to Wells Fargo's offering. The filing does not specify any immediate next steps, but the bank's ongoing engagement in capital markets suggests that further announcements may follow as they finalize the terms of the notes and gauge investor interest.
Read Next
Q/C Technologies Enters Omnibus Amendment Agreement
ONE Nuclear Energy settles consulting fees with stock issuance
HCW Biologics delays stockholder vote amid quorum issues
bioAffinity Technologies amends share structure in 8-K filing
VisionWave amends sponsorship deal with Hen Basketball Haifa Club
Apimeds Pharmaceuticals Amends Agreement with FreeT Inc.










